A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease

Plain-language summary

This study examined, in genetic and brain blood-flow (perfusion) terms, the response to cholinesterase inhibitor drugs (Rivastigmine, Aricept, Galantamine) in people with Lewy body disease. It included patients over 50 with mild-to-moderate dementia. The study was carried out as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Sunnybrook Health Sciences Centre

Intervention

Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)

Start date

9/1/2006

Estimated completion

1/1/2016

Countries

Canada

Related genes

Locations

• Toronto, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Inclusion criteria for patients with a Lewy body spectrum disorder includes: age \> 50 years; and mild-moderate dementia (Mini-Mental State Exam \[MMSE\] \> 9); contact on at least four of seven days/week with a responsible caregiver; Hoehn \& Yahr stage ≤ 4.

Exclusion Criteria:

* age \< 50; Severe dementia (MMSE \< 9); contact \< 4 days a week with a responsible caregiver; Hoehn \& Yahr stage \> 4.